Pediatric melanoma: Are recent advances in the management of adult melanoma relevant to the pediatric population

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 5, 2000, Pages 428-432

  Gibbs, Peter ^a   Moore, Anisa ^a   Robinson, William ^a   Walsh, Patrick ^a   Golitz, Loren ^a   Gonzalez, Rene ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Melanoma; Pediatric; Therapy

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; HUMAN; INFANT; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; NEWBORN; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LYMPHATIC METASTASIS; MALE; MELANOMA;

EID: 0034267126     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200009000-00008     Document Type: Article

References (15)

1. rd edition. J.B. Lippincott, 1997: 175-86.
2. Marghoob AA, Schoenbach SP, Kopf AW, et al. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol 1996; 132: 170-5.
3. Saenz NC, Saenz-Badillos J, Busam K, et al. Childhood melanoma survival. Cancer 1999; 85: 750-4.
4. Morton DL, Wen DR, Cochran AJ. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy or " watch and wait.” Surg Oncol Clin North Am 1992; 1: 247.
5. Ross MI, Reintgen DS. Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases. Eur J Cancer 1998; 34: S7-S11.
6. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-83
7. Karakousis CP. Therapeutic node dissections in malignant melanoma. Semin Surg Oncol 1998; 14: 291-301.
8. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
9. Kirkwood JM, Ibrahim J, Sondak V, et al. Role of high-dose IFN in high-risk melanoma: preliminary results of the E1690/S9111/C9190 US intergroup postoperative adjuvant trial of high and low-dose IFN2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma. Proc Am Soc Clin Oncol 1999; 35: 2072A.
10. Walsh P, Gibbs P, Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 2000; 42: 480-9.
11. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukins 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-16.
12. Anderson C, Buzaid A, Legha S. Systemic treatment of advanced cutaneous melanoma. Oncology 1995; 9: 1149-58.
13. Wallack MK, Sivanandham M, Balch CM, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75: 34-42.
14. rd edition. J.B. Lippincott, 1997: 325-72
15. Young RF. Radiosurgery for the treatment of brain metastases. Semin Surg Oncol 1998; 14: 70-8.